Nikola Panajotovikj

// PhD Researcher | AI and Drug Safety

March 27, 2026

How a diabetes drug affects the brain

When people search for “diabetes drug affects brain”, they are usually asking a surprisingly good scientific question. For a long time, diabetes drugs were mainly framed as metabolic medicines. They lower glucose, improve glycaemic control, and in some cases help with weight loss. But that picture is now incomplete. A growing body of literature suggests that some of these drugs, especially GLP-1 receptor agonists such as semaglutide, liraglutide, and lixisenatide, also affect the brain.12

That does not mean we should jump straight to hype. But it does mean that the relationship between diabetes drugs and the central nervous system is no longer a side note. It is becoming one of the most interesting parts of the story.

The short answer

Yes, some diabetes drugs do appear to affect the brain.

The clearest evidence is for GLP-1 receptor agonists. These drugs seem to influence brain regions involved in appetite, food reward, and satiety.13 That is one reason why patients often describe not just feeling full, but feeling less interested in food.

That distinction matters. Reduced eating is not only about a slower stomach or delayed gastric emptying. It may also reflect changes in how the brain processes hunger, reward, and craving.1

Why this matters

This is where the topic becomes bigger than diabetes. If a diabetes drug affects the brain, then its effects may extend beyond blood sugar control. It may change eating behaviour. It may alter reward pathways. It may influence neuroinflammation, brain energy use, or even the biology of neurodegenerative disease.24 That is why these drugs are now being discussed not only in endocrinology, but also in neurology and psychiatry.

GLP-1 drugs and the brain’s appetite circuits

One of the most convincing areas of evidence comes from human imaging studies. Research has shown that GLP-1 receptor activation can modulate activity in brain regions linked to appetite and reward.1 In practical terms, that helps explain why people taking semaglutide or liraglutide often report that food noise becomes quieter. The drugs do not just make eating physically harder. They may make food cues feel less compelling in the first place.

This is an important shift in how we think about these medicines. They are not simply acting on the pancreas and gut. They appear to be acting on a broader metabolic-brain axis.2

Do these drugs actually reach the brain?

This is a more technical question, but an important one.

A recent review asked directly whether GLP-1 receptor agonists are CNS penetrant. The answer was nuanced: there is good preclinical evidence that at least some of these drugs, including liraglutide, semaglutide, and exenatide, can engage the central nervous system, while human evidence comes more indirectly through imaging and functional studies.2

So the safest conclusion is not that every drug behaves identically, but that central effects are biologically plausible and increasingly supported by experimental and clinical data.24

Could a diabetes drug help protect the brain?

This is where the literature becomes especially interesting, and also where caution is most important.

Several studies have raised the possibility that GLP-1 drugs may have neuroprotective effects. Some observational work has linked semaglutide and tirzepatide with lower risks of dementia, stroke, and death compared with other antidiabetic drugs.5 Broader analyses have also suggested potential benefits for neurocognitive outcomes.6

But this is exactly where careful reading matters. Much of this evidence is still observational. That means it can show associations, not definitive causation. Patients receiving one drug may differ from patients receiving another in ways that are difficult to fully adjust for.

So at this point, it is fair to say that these drugs are promising for brain health research. It is not yet fair to say that they are established therapies for dementia.

Alzheimer’s disease: promising, but not settled

GLP-1 drugs have attracted attention in Alzheimer’s disease because impaired glucose handling and metabolic dysfunction are increasingly recognised as part of the disease process.

Earlier work with liraglutide suggested that treatment might help preserve cerebral glucose metabolism in people with Alzheimer’s disease.7 More recent studies have produced a more mixed picture, with some encouraging secondary signals but less clarity on primary endpoints.8

That is often how emerging translational research looks: biologically plausible, early signals of benefit, but not yet a finished clinical story.

Parkinson’s disease may be the most striking example

One of the strongest examples of a diabetes drug affecting the brain in a clinically meaningful way comes from Parkinson’s disease.

In a phase 2 trial published in the New England Journal of Medicine, lixisenatide was associated with less progression of motor disability than placebo in early Parkinson’s disease over 12 months.9 This does not prove that all GLP-1 drugs will work in neurodegeneration, but it does show that the field is serious and that the signal is not only theoretical.

This is one of the clearest examples of why drug classes should not be boxed too narrowly by their original indication.

What about mental health?

This is an area where the public conversation has sometimes moved faster than the evidence.

Some people worry about psychiatric effects, including mood changes or suicidality. So far, the evidence does not support a simple alarmist conclusion. A recent meta-analysis found no increased psychiatric adverse events in trial data and even suggested some quality-of-life improvements.10 At the same time, pharmacovigilance signals and observational concerns mean this is still an area that deserves close monitoring.11

That is probably the most honest summary: not panic, not dismissal, but continued vigilance.

TL;DR

The phrase “diabetes drug affects brain” may sound like clickbait, but the underlying question is real.

For GLP-1 receptor agonists, the literature supports a genuine effect on brain systems involved in appetite and reward.13 There is also growing interest in their possible role in cognition, stroke, and neurodegenerative disease, although that part of the evidence is still developing.56

In other words, these drugs are helping blur a boundary that was probably too rigid to begin with: the boundary between metabolic disease and brain disease.

And from a pharmacology point of view, that is a fascinating shift.

  1. van Bloemendaal L, IJzerman RG, ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196. doi:10.2337/db14-0849. ↩ ↩2 ↩3 ↩4 ↩5

  2. West J, Li M, Wong S, Le GH, Teopiz KM, Valentino K, Dri CE, McIntyre RS. Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. Neurol Ther. 2025 Aug;14(4):1157-1166. doi: 10.1007/s40120-025-00724-y. Epub 2025 Apr 2. Erratum in: Neurol Ther. 2025 Aug;14(4):1167-1168. doi: 10.1007/s40120-025-00758-2 ↩ ↩2 ↩3 ↩4 ↩5

  3. van Bloemendaal L, Veltman DJ, ten Kulve JS, et al. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by GLP-1 receptor activation in humans. Diabetes Obes Metab. 2015;17(9):878-886. doi:10.1111/dom.12506. ↩ ↩2

  4. Zheng Z, Zhou S, Li Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:221. doi:10.1038/s41392-024-01931-z. ↩ ↩2

  5. Lin HT, Xie Y, Wan EYF, et al. Neurodegeneration and stroke after semaglutide and tirzepatide versus other antidiabetic drugs among adults with type 2 diabetes, obesity, and glucose dysregulation. JAMA Netw Open. 2025;8(9):e2553304. doi:10.1001/jamanetworkopen.2025.21016. ↩ ↩2

  6. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31:1116-1126. doi:10.1038/s41591-024-03412-w. ↩ ↩2

  7. Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108. doi:10.3389/fnagi.2016.00108. ↩

  8. Edison P, Aarsland D, Ballard C, et al. Liraglutide in mild to moderate Alzheimer’s disease: a phase II randomised double-blind placebo-controlled trial. Alzheimers Dement. 2026;22(4):e70121. doi:10.1002/alz.70121. ↩

  9. Meissner WG, Schott A-M, El Fassi J, et al. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med. 2024;390(13):1176-1185. doi:10.1056/NEJMoa2312323. ↩

  10. Pierret ACS, Mizuno Y, Saunders P, et al. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(7):643–653. doi:10.1001/jamapsychiatry.2025.0679 ↩

  11. Valentino K, Teopiz KM, Cheung W, Wong S, Le GH, Rosenblat JD, Mansur RB, McIntyre RS. The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review. J Psychiatr Res. 2025 Mar;183:112-126. doi: 10.1016/j.jpsychires.2025.02.008. ↩

Back to blog